Cargando…
Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer
The efficacy and safety of immune checkpoint inhibitor (ICI) monotherapy in elderly patients with non‐small cell lung cancer (NSCLC) remain unclear, especially in patients older than 80 years. We retrospectively reviewed the records of 10 patients older than 80 years with NSCLCs treated by ICIs. The...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954839/ https://www.ncbi.nlm.nih.gov/pubmed/33738379 http://dx.doi.org/10.1002/agm2.12147 |